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Abstract
The Insulin Receptor Substrate (IRS) proteins are cytoplasmic adaptor proteins that function as
essential signaling intermediates downstream of activated cell surface receptors, many of which
have been implicated in cancer. The IRS proteins do not contain any intrinsic kinase activity, but
rather serve as scaffolds to organize signaling complexes and initiate intracellular signaling pathways.
As common intermediates of multiple receptors that can influence tumor progression, the IRS
proteins are positioned to play a pivotal role in regulating the response of tumor cells to many
different microenvironmental stimuli. Limited studies on IRS expression in human tumors and
studies on IRS function in human tumor cell lines and in mouse models have provided clues to the
potential function of these adaptor proteins in human cancer. A general theme arises from these
studies; IRS-1 and IRS-4 are most often associated with tumor growth and proliferation and IRS-2
is most often associated with tumor motility and invasion. In this review, we discuss the
mechanisms by which IRS expression and function are regulated and how the IRS proteins
contribute to tumor initiation and progression.
Introduction
The Insulin Receptor Substrate (IRS) proteins are a family
of cytoplasmic adaptor proteins that were first identified
for their role in insulin signaling. The first family member
to be identified, IRS-1, was initially characterized as a 185
kD phosphoprotein that was detected in anti-phosphoty-
rosine immunoblots in response to insulin stimulation
[1]. IRS-2 was discovered as an alternative insulin receptor
substrate, initially named 4PS, in insulin-stimulated cells
derived from Irs-1-/- mice [2]. IRS-1 and IRS-2 are ubiqui-
tously expressed and are the primary mediators of insulin-
dependent mitogenesis and regulation of glucose metab-
olism in most cell types (reviewed in [3]). Humans
express one additional family member, IRS-4, which is
more restricted in its expression pattern and is found pri-
marily in brain, kidney, thymus and liver [4]. A fourth IRS
protein, Irs-3, is expressed in rodents, but not in humans
[5,6]. More distantly related IRS family members IRS-5
and IRS-6, also known as DOK4 and DOK5, share homol-
ogy in their N-termini, but have truncated C-termini [7-9]
(Figure 1). Despite their significant homology, it is clear
from the genotypes of knockout mice that the IRS proteins
have non-redundant normal functions. Irs-1-/- mice are
born small and remain runted throughout their lives,
implicating a role for this IRS protein in somatic growth
regulation [10,11]. A similar contribution of the IRS
homolog Chico to the regulation of cell size and growth
in Drosophila has been observed [12]. Mice deficient for
Irs-1 develop insulin resistance but do not progress to dia-
betes because they maintain normal pancreatic β-cell
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numbers. Irs-2-/- mice are normal in size but have brain
defects, the result of a 50% decrease in neuronal prolifer-
ation [13,14]. In contrast to Irs-1-/- mice, Irs-2-deficient
mice develop early-onset diabetes due to a combination
of peripheral insulin resistance and a loss of β-cell func-
tion [13,15]. Irs-2-/-  females are also infertile, which
together with evidence from insulin-signaling in Dro-
sophila and C. elegans, supports a conserved mechanism
for integrating reproduction and metabolism [16]. Irs-4-/-
mice are phenotypically normal, with only mild growth,
reproductive and insulin sensitivity defects [17]. These
differences in IRS function in normal development and
physiology are also evident in cancer.
The IRS proteins contain no intrinsic enzymatic activity
and they contribute to signaling through their function as
adaptors to organize signaling complexes [18]. They share
their highest level of homology in their N-termini, which
contain two highly conserved domains that contribute to
their recruitment to activated upstream receptors. The first
of these domains is the pleckstrin homology (PH)
domain. The PH domain is hypothesized to mediate both
protein-protein interactions that facilitate the recruitment
of the IRS proteins to receptors, and protein-phospholipid
interactions that localize the IRS proteins to the cell mem-
brane, in close proximity to transmembrane receptors
[19-21]. The second conserved region is the phosphotyro-
sine binding (PTB) domain, which interacts with NPXY
motifs in activated receptors [22,23]. An additional motif
that contributes to receptor recruitment, the kinase regu-
latory loop binding (KRLB) domain, has been identified
only in IRS-2 (Fig. 1)[22,24]. Upon binding to upstream
receptors, the IRS proteins are phosphorylated on tyrosine
residues in their C-termini, generating binding sites that
recruit downstream effectors [25,26]. Effectors that have
been characterized to bind to the IRS proteins include
PI3K, Grb-2, SHP-2, Fyn, c-Crk, CrkII and Nck [9,27-32].
A recent study that utilized phosphorylated bait peptides
to profile all potential phosphotyrosine dependent inter-
action sites in IRS-1 and IRS-2 identified additional
potential interacting proteins [33]. However, additional
studies will be necessary to determine if these effectors are
recruited to the intact IRS proteins in response to physio-
logical stimuli. It is the combined action of the down-
stream effectors that determine the signals that are
transmitted through the IRS proteins and the cellular
response that occurs (Figure 2). Importantly, many of
these effector-signaling pathways have been implicated in
tumorigenesis and cancer progression.
Schematic of the IRS protein family Figure 1
Schematic of the IRS protein family. Interaction domains of the IRS proteins are indicated. PH (purple), pleckstrin homol-
ogy domain; PTB (purple), phosphotyrosine binding domain; KRLB (pink), kinase regulatory loop binding domain; PI3K 
(orange), region containing multiple PI3K binding motifs; Grb-2 (green), Grb-2 binding site; SHP-2 (yellow), SHP-2 binding site. 
IRS-5 and IRS-6 contain regions of similarity to each other in their C-termini (light purple).
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Expression of the IRS proteins in human cancer
There are relatively few reports on the expression patterns
of the IRS adaptor proteins in human tumors, either at the
mRNA or protein level. The majority of these studies have
evaluated the expression of IRS-1 and IRS-2, which are the
more ubiquitously expressed family members in normal
tissue. As an overall summary, IRS expression is most
often elevated in human tumors when compared with
normal tissue (Table 1). Expression of both IRS-1 and IRS-
2 is reported to be increased in hepatocellular, pancreatic
and prostate cancer and malignant pleural mesothelioma
[34-40]. In other cancers, including breast, ovarian and
medulloblastoma, only IRS-1 expression has been evalu-
ated and a similar trend toward increased expression in
primary tumors has been reported [41-44]. However, in
breast cancer, which has been studied the most exten-
Signaling via the IRS proteins Figure 2
Signaling via the IRS proteins. The IRS proteins are recruited to activated cell surface receptors via PH/PTB domains in 
their N-termini. Once bound, they are phosphorylated on tyrosine residues in their C-termini. The phosphorylation of tyro-
sine residues (pY) creates docking sites for the recruitment of downstream signaling effectors. Subsequently, signaling cascades 
are activated that can regulate gene expression, protein synthesis, glycolysis, cell proliferation, survival and motility/invasion.
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sively of all cancers for IRS expression, there is also evi-
dence that the expression of IRS-1 could correlate
negatively with tumor progression. Specifically, IRS-1 is
expressed at moderate to strong levels in normal tissue
and well-differentiated carcinomas, but expression
decreases in more poorly differentiated, higher-grade
tumors [45,46]. Decreased IRS-1 expression is also
observed in some non-small cell lung cancers (NSCLC),
and this lower expression occurs more frequently in squa-
mous cell carcinomas [47]. The conclusion drawn from
the lung cancer study was that downregulation of IRS-1
may be an early event in NSCLC development. To date,
the only study to examine IRS-4 expression in human can-
cer reported increased expression in hepatocellular carci-
noma [39]. Finally, both IRS-2 and IRS-5 are upregulated
at the level of gene expression in clear cell renal cell carci-
noma [48]. One caveat to all of these expression studies,
however, is that the IRS proteins can be phosphorylated
on serine residues through negative feedback loops,
which inhibits their function (reviewed in [49]). There-
fore, expression of the IRS proteins may not reflect the
functional status of these adaptor proteins. Additional
studies are needed to establish clearly the expression and
function of the IRS proteins in human cancer and to deter-
mine if their relative expression levels have prognostic or
predictive value.
Upstream receptors implicated in cancer
The IRS proteins function as essential signaling intermedi-
ates downstream of many cell surface receptors that have
been implicated in cancer. For example, the IRS proteins
are major downstream effectors of the Insulin-Like
Growth Factor-1 (IGF-1) receptor (IGF-1R) and they play
a critical role in determining the cellular response to IGF-
1 stimulation [50]. There is a strong correlation between
enhanced IGF-1-mediated signaling and a wide range of
cancers including malignancies of the breast, colon, pros-
tate, thyroid, liver, pancreas and central nervous system
[51]. In breast cancer, IGF-1 expression is elevated in the
serum of patients and the IGF-1R is frequently over-
expressed and is a prognostic indicator of tumor recur-
rence and reduced patient survival [52,53]. Other growth
factor/hormone receptors that signal through the IRS pro-
teins and that are associated with cancer include the insu-
lin, prolactin, growth hormone (GH), and vascular
endothelial growth factor (VEGF; KDR) receptors [54-56].
The IRS proteins have also been implicated in signaling
downstream of the EGF receptor (EGFR), which may
involve an EGFR/IGF-1R cross-talk [57,58]. Some integrin
adhesion receptors also utilize the IRS proteins as signal-
ing intermediates to relay intracellular signals [59-61]. In
addition to surface receptors, several oncogenic fusion
proteins that arise as the result of chromosomal transloca-
Table 1: IRS expression in human cancer
Cancer Type IRS
Expression
Notes Ref(s)
Breast ↑ IRS-1 Well differentiated primary tumors [41,43]
↑ IRS-1 Nuclear IRS-1 correlates with good prognosis [46]
↓ IRS-1 Poorly differentiated, high grade tumors [45,46]
Hepatocellular ↑ IRS-1 mRNA/protein increased in HCC [38,39]
↑ IRS-2 mRNA/protein increased in HCC [38,39]
↑ IRS-4 mRNA increased in HCC [39]
Lung ↓ IRS-1 Larger (stage 1B) tumors, squamous cell carcinoma [47]
Medulloblastoma ↑ IRS-1 Co-localized with polyoma JCV T-antigen in nucleus [42]
Mesothelioma ↑ IRS-1 mRNA increased in malignant pleural mesothelioma [37]
↑ IRS-2 mRNA increased in malignant pleural mesothelioma [37]
Ovarian ↑ IRS-1 Protein increased in malignant epithelial tumors [44]
Pancreatic ↑ IRS-1 mRNA increased in 7/16 tumors [34]
↑ IRS-2 mRNA/protein increased in ductal-like cancer cells [35]
Prostate ↑ IRS-1 Protein increased in tumors and metastases [36]
↑ IRS-2 Protein correlates with increased Myc expression [40]
Renal ↑ IRS-2 mRNA increased in clear cell carcinomas [48]
↑ IRS-5 mRNA increased in clear cell carcinomas [48]Cell Communication and Signaling 2009, 7:14 http://www.biosignaling.com/content/7/1/14
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tions have also been reported to signal through the IRS
adaptor proteins for their tumor promoting functions.
These include the ETV6-NTRK3 gene fusion found in
pediatric spindle cell sarcomas and secretory breast can-
cer, the RET-PTC3 gene fusion found in papillary thyroid
cancer and the NPM-ALK gene fusion that is a transform-
ing oncogene found in anaplastic large-cell lymphoma
[62-64]. Full length anaplastic lymphoma kinase (ALK), a
member of the insulin receptor superfamily and receptor
for the growth factor pleiotrophin, also signals through
the IRS proteins. ALK is expressed in breast and pancreatic
carcinomas, melanoma and neuroblastoma, and has been
demonstrated to be rate limiting for glioblastoma growth
[65]. As common intermediates of many receptors that
can influence tumor progression, the IRS proteins are
positioned to play a key role in regulating the response of
tumor cells to microenvironmental stimuli. As a result,
they are also attractive candidates to be targets for interfer-
ing with the tumor-promoting signals that are initiated
through these disparate receptors.
IRS function in cancer
There are many studies on IRS function in human tumor
cell lines and in mouse models that provide clues to the
potential function of these adaptor proteins in human
cancer. A general theme arises from these studies; IRS-1
and IRS-4 are most often associated with tumor growth
and proliferation and IRS-2 is most often associated with
tumor motility and invasion.
IRS-1
IRS-1 involvement in regulating tumor cell proliferation
was foreshadowed by its role in somatic growth regula-
tion. IRS-1 null mice are approximately 30% smaller than
wildtype littermates and they maintain their runted phe-
notype throughout life [10,11]. IRS-1 is the predominant
IRS family member that is activated by IGF-1 in well-dif-
ferentiated estrogen receptor positive (ER+) human breast
carcinoma cell lines [66,67]. IRS-1 mediates IGF-1-
dependent growth in these cells, which has also been
observed for hepatocellular and prostate carcinoma,
medulloblastoma and malignant pleural mesothelioma
cell lines [37,66-70]. The activation of both MAPK and
PI3K signaling pathways has been implicated in the stim-
ulation of proliferation by IRS-1 [67,69,71,72]. IRS-1-
dependent signals also contribute to tumor cell survival.
Suppression of IRS-1 expression by siRNA promotes
apoptosis and renders ER+ breast carcinoma cells more
sensitive to tamoxifen-stimulated cell death, whereas
overexpression of IRS-1 confers resistance to TGF-β-
induced cell death in hepatocellular carcinoma cells
[73,74]. In contrast, Irs-1-/- mammary tumor cells derived
from mouse mammary tumor virus (MMTV)-polyoma
virus middle T antigen (PyV-MT) mice are more resistant
to apoptosis in response to serum deprivation than
wildtype cells [75].
Transgenic mouse models have provided important infor-
mation regarding IRS-1 function in cancer. Overexpres-
sion of IRS-1 in the mouse mammary gland results in
mammary hyperplasia and tumorigenesis, which corre-
lates with constitutive tyrosine phosphorylation of IRS-1,
activation of Akt and Erk1/2 and association with β-cat-
enin [76]. In mouse hepatocytes, overexpression of IRS-1
increases DNA synthesis and hepatic mass by 25%, further
supporting the connection between IRS-1 and prolifera-
tion [77]. However, liver tumors do not develop in these
transgenic mice, possibly because Fas-receptor is upregu-
lated and this pro-apoptotic signal balances the pro-
growth signals from IRS-1 [78]. The different results of
these transgenic models with regard to tumorigenesis sug-
gest that the oncogenic potential of IRS-1 may be depend-
ent upon cellular context. Although IRS-1 overexpression
promotes tumorigenesis, IRS-1 is not required for primary
tumor growth as demonstrated by the fact that mammary
tumor initiation and growth are not prevented or delayed
in Irs-1-/- mice in response to the PyV-MT antigen when
compared with tumors that develop in wildtype litterma-
tes [79]. One important caveat to the IRS overexpression
and knockout mouse mammary tumor studies is that the
tumors that develop in both models are ER- and a possi-
ble preferential role for IRS-1 in ER+ tumor growth, which
is suggested from the studies on human breast carcinoma
cell lines, cannot be excluded. In contrast with the positive
role for IRS-1 in early tumor development and growth,
IRS-1 may play a suppressive role in tumor progression.
Specifically,  PyV-MT:Irs-1-/-  mammary tumors have a
greater incidence and rate of lung metastasis when com-
pared with PyV-MT:WT tumors [79,80]. Together with the
IRS-1 expression data in human breast and lung cancer,
these results reveal that loss of IRS-1 expression or func-
tion may facilitate tumor progression [45-47]. Once
again, however, it is likely that IRS-1 function is cell con-
text-dependent because deletion of Irs-1 in Apcmin-/
+(Min)/β-catenin-derived intestinal tumors decreases
tumor incidence and growth and increases irradiation-
induced apoptosis in the intestinal crypt [81].
IRS-2
The association of IRS-2 with tumor progression was first
indicated by the finding that inhibition of the IGF-1R in
ER- breast carcinoma cells, which express IRS-2 and lack
or have decreased IRS-1 expression, does not inhibit
tumor proliferation. However, inhibition of IGF-1R func-
tion does prevent metastasis of these cells in xenograft
models [82,83]. Several studies have since demonstrated
that IGF-1 promotes cell motility and invasion in human
breast carcinoma cell lines and mouse mammary tumor
cells that signal preferentially through IRS-2, but not inCell Communication and Signaling 2009, 7:14 http://www.biosignaling.com/content/7/1/14
Page 6 of 15
(page number not for citation purposes)
cell lines that express only IRS-1 [70,84-86]. A similar role
for IRS-2-dependent signaling in cell motility and inva-
sion has been reported for neuroblastoma and mesotheli-
oma cells [37,87]. In contrast to IRS-2, IRS-1 may suppress
cell migration because expression of IRS-1 in LnCAP pros-
tate carcinoma cells decreases their motility. One possible
mechanism by which IRS-2 contributes to tumor progres-
sion and cell invasion is by positively regulating aerobic
glycolysis via the enhanced localization of the GLUT-1
glucose transporter on the tumor cell surface [88]. Similar
to IRS-1, IRS-2 has also been implicated in promoting
tumor cell survival, which is likely to contribute to its role
in tumor progression. Irs-2-deficient PyV-MT-derived
mammary tumor cells are significantly more sensitive to
serum deprivation-induced apoptosis than wildtype
tumor cells, and Irs-2-/- tumors also have a higher in situ
level of apoptosis [75]. Suppression of IRS-2 expression in
hepatocellular carcinoma cells that express high levels of
this adaptor protein also results in apoptosis [38]. Recent
studies in pancreatic adenocarcinoma cells reveal that IRS-
2 can regulate the expression of the IGF-1R to sustain high
levels of IGF-1-dependent signaling [89]. Therefore, IRS-2
may promote tumor progression by stimulating a positive
feedback loop to enhance IGF-1 signaling.
Additional support for IRS-2 as a positive regulator of
tumor progression comes from in vivo mouse model stud-
ies. Mammary tumor metastasis is significantly dimin-
ished in PyV-MT:Irs-2-/- mice, and Irs-1 deficient tumors
that express elevated levels of active (i.e. tyrosine phos-
phorylated) Irs-2 have enhanced metastatic rates [75,79].
Irs-2 expression is elevated in tumors that arise in PTEN+/
- mice, and deletion of Irs-2 has no impact on tumor initi-
ation, but it does suppress tumor growth and progression
to invasive disease [40]. IRS-2, like IRS-1, can promote
tumor initiation and progression when this adaptor pro-
tein is overexpressed in the mammary gland, a finding
that would appear to conflict with the inability of IRS-2 to
regulate tumor proliferation in human breast carcinoma
cell lines [70,76]. One possible explanation for this dis-
crepancy is that functions that are not observed at normal
expression levels are gained when IRS expression levels
are elevated. Alternatively, IRS-1 and IRS-2 may contrib-
ute to early tumorigenesis through distinct mechanisms.
That is, IRS-1 may promote enhanced proliferation,
whereas IRS-2 may promote enhanced survival, with the
common outcome being tumorigenesis and progression.
The differential abilities of IRS-1 and IRS-2 to promote
proliferation and motility/invasion, respectively, raises
the question of how these similar proteins regulate diver-
gent functions. IRS-1 and IRS-2 share approximately 35%
identity in their C-termini where they recruit downstream
effectors to phosphotyrosine binding motifs to initiate
their signaling cascades. Many of the motifs are conserved
between the two family members, and IRS-1 and IRS-2
have been reported to activate common signaling path-
ways including PI3K and the Erk1/2 MAPK kinases in a
variety of cancer model systems [29,60,69,90,91]. Both of
these signaling pathways have been implicated in promot-
ing tumor cell proliferation, invasion and survival, but
they cannot explain the differential abilities of IRS-1 and
IRS-2 to regulate these functions. One potential mecha-
nism for IRS-specific regulation of tumor cell functions is
the recruitment of effectors to unique binding motifs in
the C-termini of the IRS proteins that activate signaling
pathways selectively downstream of either IRS-1 or IRS-2.
For example, Rho-kinase (ROCK), which regulates cell
adhesion and motility, is reported to be activated down-
stream of IRS-2 [91]. A recent proteomic analysis of
potential IRS-1 and IRS-2 interacting partners provides
further evidence that unique effectors can interact with
each adaptor protein [33]. Distinct intracellular compart-
mentalization of IRS-1 and IRS-2 or differential sensitivi-
ties of IRS-1 and IRS-2 to negative feedback regulation
would also impact the signaling outcomes of these adap-
tor proteins [49,92]. Additionally, acetylation positively
regulates tyrosine phosphorylation of IRS-1 and nega-
tively regulates tyrosine phosphoryaltion of IRS-2, which
demonstrates that the function of these adaptor proteins
can be differentially regulated by post-translational mod-
ifications [93-95].
An alternative mechanism for the differential involve-
ment of IRS-1 and IRS-2 in cancer that would allow for the
activation of a common signaling pathway by these adap-
tor proteins was revealed during the analysis of Irs1-/-
mammary tumors. Akt and mTor activation were
enhanced significantly in Irs1-/- mammary tumors when
compared with the level of activation in wildtype tumors
[79]. Although signaling through IRS-1 can activate these
pathways in response to insulin or IGF-1 in many other
model systems, when Irs-2 expression and function were
compared between Irs1-/- and WT  tumors, Irs-2 activity
was significantly higher in the absence of Irs-1, a finding
that is mimicked by transient suppression of Irs-1 by
siRNA in vitro [79]. A corresponding upregulation of Irs-1
expression and function is not observed in Irs-2-/- tumors,
or when Irs-2 expression is suppressed by siRNA (S. Pank-
ratz, personal observation). Importantly, suppression of
Irs-2 expression in Irs1-/- tumor cells restores mTor activa-
tion to wildtype levels, confirming the contribution of Irs-
2 to the increased mTor activity [79]. These in vitro find-
ings support the hypothesis that Irs-2 compensates for the
loss of Irs-1, and in doing so, enhances the activation of
signaling pathways that promote tumor metastasis. A sim-
ilar compensatory upregulation of Irs-2 expression in Irs-
1-/- mouse embryo fibroblasts has been hypothesized to
explain the dominant role that IRS-2 plays in metabolic
regulation [96].Cell Communication and Signaling 2009, 7:14 http://www.biosignaling.com/content/7/1/14
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IRS-4
IRS-4 expression increases in response to partial hepatec-
tomy, a liver regeneration model, and expression is higher
in hepatocellular tumors when compared with normal
liver tissue [39,97]. In HepG2 hepatocellular carcinoma
cells, suppression of IRS-4 expression by siRNA decreases
IGF-1-dependent proliferation, which correlates with
reduced Erk and p70S6-kinase activation [98]. Irs-4 has
also been implicated in the insulin-dependent prolifera-
tion of a murine T-cell lymphoma cell line and it is over-
expressed in a pediatric T-cell acute lymphoblastic
leukaemia (T-ALL) that harbors a breakpoint fusion
between the T-cell receptor beta locus and the IRS-4 gene
[99,100]. These studies suggest that IRS-4 functions more
similarly to IRS-1 than IRS-2 in cancer in that it is associ-
ated with tumor proliferation.
Regulation of IRS expression
The evidence supporting the contribution of the IRS pro-
teins to both tumor initiation and progression highlights
the importance of understanding how the expression of
these adaptor proteins is regulated. The differential
expression patterns of the IRS proteins in both normal tis-
sues and tumors support that their expression is likely reg-
ulated by unique mechanisms. Both the IRS-1 and IRS-2
genes are hormone-responsive, with IRS-1 regulated by
the ER and IRS-2 regulated by the progesterone receptor
(PR). Estrogen upregulates IRS-1 in ER+ breast carcinoma
cells and IRS-1 expression decreases in response to the ER
antagonists tamoxifen and ICI 182,780 [101-104]. This
inhibition of IRS-1 expression may contribute to the sup-
pression of breast cancer by these antiestrogens [101,102].
Progestin stimulation prior to IGF-1 treatment of PR+
breast carcinoma cells upregulates IRS-2 expression levels
and tyrosine phosphorylation, thereby enhancing down-
stream IRS-2-dependent signals [105-107].
Non-hormone-dependent pathways also regulate the IRS
genes. E-box elements in the IRS-1 promoter and proteins
that bind to these elements positively regulate IRS-1
expression in HepG2 hepatocellular carcinoma cells
[108]. E-boxes are often found in promoters of genes
involved in metabolism and are consensus cis-elements
for members of the basic helix-loop-helix family of tran-
scription factors. IRS-2 is positively regulated by the
cAMP-mediated activation of CREB, a pathway that is
essential for the expression of this adaptor protein in pan-
creatic β-cells [109]. Members of the Forkhead transcrip-
tion family, including FOXO1 and FOXO3a, can also
positively regulate IRS-2 expression [110]. Several growth
factor/hormone signaling pathways that are associated
with cancer including fibroblast growth factor (FGF), epi-
dermal growth factor (EGF) and insulin can modulate
IRS-1 and IRS-2 expression levels [86,111-113]. The EGF-
induced upregulation of IRS-2 expression occurs through
a JNK/c-Jun/AP-1 pathway [86]. IRS-1 expression is nega-
tively regulated by all-trans retinoic acid (ATRA), which
arrests the growth of ovarian carcinoma cells in G0–G1
[44].
Amplified in breast cancer 1 (AIB1), also known as steroid
receptor coactivator-3 (SRC-3), regulates both IRS-1 and
IRS-2 expression [114,115]. AIB1 is an oncogene that is
often overexpressed in human tumors and it promotes the
growth of hormone-insensitive tumor cells through its
action as a coactivator of nuclear receptors [116]. AIB1
directly regulates IRS-1 transcription by cooperating with
the AP-1 transcription factor [115]. The importance of this
IRS-1 regulatory pathway is demonstrated by the fact that
deletion of AIB1 has a protective effect on mouse mam-
mary glands against carcinogen-induced tumorigenesis,
which can be explained in part by decreased IRS-1 expres-
sion and decreased Akt signaling [117]. The breast cancer-
associated gene-1 (BRCA1) is a tumor suppressor that is
mutated or deleted in 10% of hereditary breast cancers
[118]. BRCA1 interacts directly with the IRS-1 promoter
and inhibits transcription of the IRS-1 gene through epi-
genetic modification of histone H3 and H4 [119]. Dele-
tion of BRCA1 in mice leads to increased expression of
some members of the IGF-1 signaling pathway, including
IRS-1 [119]. The association of IRS-1 expression with
BRCA1 provides additional support for the involvement
of this IRS family member in tumor initiation.
At the post-transcriptional level, two microRNAs, miR-
126 and miR-145, have been identified that target and
suppress IRS-1 protein expression [120-122]. Both miR-
126 and miR-145 inhibit cell growth and their expression
is frequently decreased in many cancer types
[120,121,123,124]. Taken together, these findings are in
keeping with a growth-promoting role for IRS-1 in
tumors. miR-145 has also been implicated in positively
regulating embryonic stem cell differentiation [125].
Interestingly, IRS-1 promotes stem cell self-renewal and
its expression decreases during embryonic stem cell differ-
entiation when miR-145 expression increases [126]. To
date, miRNAs that target other IRS family members have
not been identified.
Feedback regulation of IRS function and expression
The expression and function of the IRS proteins can be
regulated post-translationally. Negative feedback regula-
tion of the IRS proteins by serine phosphorylation was
first demonstrated in insulin-dependent signaling, and
this feedback pathway is essential for regulating insulin
sensitivity and glucose homeostasis by limiting the mag-
nitude and duration of the insulin signaling response
[49,127-129]. Serine phosphorylation of the IRS proteins
interferes with their function by targeting these adaptor
proteins for inactivation and/or proteasomal degradationCell Communication and Signaling 2009, 7:14 http://www.biosignaling.com/content/7/1/14
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(Figure 3) [49]. Phosphorylation on specific residues,
such as serines 302 and 307, disrupts IRS-1 function by
inhibiting interactions between the IRS-1 PTB domain
and upstream receptors [130,131]. As a result, IRS-1 is not
phosphorylated on tyrosine residues and cannot organize
downstream signaling complexes [130,132]. IRS-1 and
IRS-2 have also been shown to interact with 14-3-3 pro-
teins through phosphoserine residues within the PTB
domain [133]. Binding of 14-3-3 proteins to the PTB
domain may physically prevent the IRS proteins from
interacting with upstream receptors, which prevents IRS-
mediated signaling.
Serine phosphorylation of the IRS proteins can also
directly interfere with interactions with downstream effec-
tors and selectively prevent their activation [131,134]. For
Negative feedback regulation of IRS-1 Figure 3
Negative feedback regulation of IRS-1. Serine residues that are phosphorylated in IRS-1 and the kinases that target these 
sites are indicated. Kinases shown in purple mediate signaling events that impede IRS-1 localization to the membrane or 
upstream receptors by disrupting PH and/or PTB domain function. Kinases shown in orange mediate signaling events that inter-
fere with PI3K recruitment and activation. Kinases shown in pink mediate signaling events that result in phosphorylation of 
S789. Kinases that initiate signaling events that result in phosphorylation of S1223 and interfere with SHP-2 binding are 
unknown (yellow). Exogenous stimuli that have been implicated in cancer and that can activate kinases to regulate IRS-1 serine 
phosphorylation are indicated.
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example, phosphorylation of serine residues within the
PI3K-binding region can inhibit interactions between the
IRS proteins and p85, the regulatory subunit of PI3K
[135]. In metastatic mouse mammary tumors, Irs-1 is
phosphorylated on serine residues in the PI3K binding
region and the association with p85 is decreased when
compared with non-metastatic tumors [79]. Phosphoryla-
tion of serine-1223 in IRS-1 interferes with recruitment of
the tyrosine phosphatase SHP-2 and, as a result, IRS-1
tyrosine phosphorylation is enhanced [136]. As men-
tioned previously, the distinct functions of IRS-1 and IRS-
2 in tumor progression may reflect a differential sensitiv-
ity of IRS-1 and IRS-2 to the effects of negative feedback
regulation, which could alter the longevity and intensity
of signals initiated through each adaptor protein
[112,137,138].
In addition to disrupting protein-protein interactions, ser-
ine phosphorylation of IRS-1 and IRS-2 can target these
adaptor proteins for ubiquitination and degradation via
the 26S proteasome [139-141]. This downregulation is
mediated by an mTOR-dependent negative feedback loop
that also involves p70S6-kinase [134,142-145]. In an
extreme example of this negative feedback, tumors with
constitutive activation of mTOR, such as those with muta-
tions in the TSC-1 or TSC-2 genes, are benign and rarely
progress to a more malignant state because both IRS-1 and
IRS-2 are degraded and cannot sufficiently activate sur-
vival signals [143,144,146]. mTOR can also regulate pro-
teasome-dependent degradation of the IRS proteins by
stimulating the endoplasmic reticulum stress (ER-stress)
response. Loss of TSC function and subsequent mTORC1
activation lead to ER-stress and activation of the unfolded
protein response (UPR) [147]. Inhibition of ER-stress in
TSC-1-/- or TSC-2-/- cells that have decreased expression of
IRS-1 and IRS-2 results in increased IRS protein stability
and insulin-induced tyrosine-phosphorylation, which
leads to enhanced Akt activation. Likewise, induction of
ER-stress dramatically increases IRS-1 ubiquitination-
dependent proteasomal degradation [147].
A significant amount of research has focused on under-
standing the contribution of IRS serine phosphorylation
to insulin resistance and diabetes and the information
gained from these studies can be applied to cancer
(reviewed in [49]) (Figure 3). For example, the inflamma-
tory cytokine tumor necrosis factor-α (TNF-α) inactivates
IRS-1 through a JNK-mediated phosphorylation of S307
(S312 in human IRS-1), which results in insulin resistance
[127,131]. Inflammatory cells in the tumor microenvi-
ronment secrete TNF-α and other cytokines that positively
contribute to tumor progression. Therefore, serine phos-
phorylation of the IRS proteins may be a mechanism by
which the stromal microenvironment influences tumor
behavior [148]. Additional exogenous factors that can reg-
ulate IRS serine phosphorylation levels and that are asso-
ciated with cancer progression include elevated free fatty
acids, obesity and oxidative stress [149-152]. Potential
intrinsic mechanisms to phosphorylate and regulate IRS
function include many kinases that are activated by onco-
genic signaling, including mTor, Akt, multiple PKC family
members, Erk1/2, S6-kinase, IKKβ, AMPK and SIK, as well
as the aforementioned JNK [49,153]. Additional studies
are warranted to determine the potential of these IRS feed-
back pathways as therapeutic targets for cancer treatment.
IRS signaling functions can be influenced by additional
post-translational modifications including O-linked glyc-
osylation and, as mentioned previously, acetylation.
Increased activation of the hexosamine pathway (HBP)
can induce O-glycosylation of IRS-1 and IRS-2, which
decreases IRS tyrosine-phosphorylation and prevents acti-
vation of the PI3K signaling pathway [154,155]. Acetyla-
tion of IRS-1 and IRS-2 decreases or increases,
respectively, their level of tyrosine phosphorylation and
downstream signaling. IRS-1 deacetylation is mediated by
HDAC2 and IRS-2 deacetylation is mediated by SirT1 [93-
95]. However, neither of these IRS posttranslational mod-
ifications have been investigated in the context of cancer
and it is not known if they contribute to the regulation of
IRS-dependent signaling in tumor cells.
Involvement of the IRS proteins in transformation
The transforming potential of the IRS proteins has been
demonstrated in several different model systems, with
most of the evidence coming from studies on IRS-1. The
earliest indication that IRS-1 had oncogenic potential
came from studies on IGF-1R  null 3T3 fibroblasts (R-
cells), which are resistant to transformation by a number
of oncogenes, including SV40 T-antigen [156,157]. Over-
expression of IRS-1 in these R- cells cooperates with both
SV40 T-antigen and Src to promote transformation,
whereas in wildtype 3T3 cells, suppression of IRS-1
expression inhibits SV40 T-antigen-mediated transforma-
tion [158,159]. Subsequent studies have demonstrated
that overexpression of IRS-1 in 3T3 fibroblasts, independ-
ent of SV40 T-antigen, promotes growth in soft agar and
tumorigenicity in nude mice [160]. IRS-1 also cooperates
with V-HA-Ras to transform 32D murine hematopoietic
cells [161]. IRS-1 tyrosine phosphorylation and activation
of MAPK, SHP-2 and PI3K signaling pathways have been
implicated in the mechanism by which this adaptor pro-
tein promotes transformation [161-163]. Overexpression
of both IRS-1 and IRS-2 in immortalized mammary epi-
thelial cells disrupts normal luminal differentiation and
polarization and promotes dysregulated growth [76].
Moreover, as mentioned previously, transgenic overex-
pression of IRS-1 or IRS-2 in the mammary gland results
in hyperplasia, tumor development and metastasis.
Tumors that arise in response to overexpression of IRS-1Cell Communication and Signaling 2009, 7:14 http://www.biosignaling.com/content/7/1/14
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and IRS-2 have increased β-catenin signaling as evidenced
by the upregulation of downstream target genes cyclin D1
and c-Myc [76]. These in vivo studies confirm the onco-
genic potential of both of these adaptor proteins.
IRS-1 has been implicated in the development of medul-
loblastomas through an interaction with the T-antigen of
human polyomavirus JC (JCV T-antigen). Medulloblast-
oma cell lines and biopsies express high levels of the IGF-
1R and IRS-1, the latter of which co-localizes with the JCV
T-antigen in the nucleus [164]. Disruption of the interac-
tion between IRS-1 and the JCV T-antigen using a domi-
nant negative mutant of IRS-1 inhibits the anchorage-
independent growth and survival of JCV T-antigen trans-
formed medulloblastoma cells [164]. More recently IRS-1
and IRS-4 have been shown to play a role in transforma-
tion by adenovirus 5 early region 1A (Ad5E1A) by binding
to the Ad5E1A protein [165]. Ad5E1A association with the
IRS proteins results in increased IRS tyrosine phosphor-
ylation and subsequent constitutive activation of the
PI3K/Akt signaling pathway.
Nuclear functions for the IRS proteins
The majority of studies that have investigated IRS function
in cancer have focused on their role as cytoplasmic adap-
tor proteins. However, there is accumulating evidence that
the IRS proteins may also have important functions in the
nucleus. As mentioned above when discussing the trans-
forming potential of the IRS proteins, IRS-1 co-localizes
with the SV40 and JCV T-antigens in the nuclei of trans-
formed cells [166,167]. Independently of any oncogenic
stimulus, IGF-1 stimulation can also promote the nuclear
localization of IRS-1 [168]. Recently, a positive correla-
tion between IRS-1 nuclear expression and a more well-
differentiated, non-metastatic phenotype for ductal breast
cancer was reported [46]. These findings provide addi-
tional evidence that the IRS proteins may have distinct
functions that are dependent upon their localization
within the cell and that the activity of these adaptor pro-
teins can be regulated by recruitment to or exclusion from
a specific intracellular compartment.
With regard to function in the nucleus, IRS-1 can be
detected on promoter sequences of several genes, includ-
ing c-myc, Cyclin D1 and ER target genes [169,170]. Stud-
ies in breast carcinoma cells reveal interactions between
IRS-1 and the transcription factors β-catenin, ER-α and the
androgen receptor (AR) [76,169,171,172]. Interactions of
IRS-1 with β-catenin and AR positively regulate transcrip-
tion, whereas IRS-1 antagonizes ER-dependent expression
of genes that contain estrogen response elements (EREs)
[169]. Although IRS-1 is capable of directing nuclear
localization of β-catenin, ER-α is responsible for the
nuclear translocation of IRS-1 in response to estrogen
treatment [169]. IRS-1 also interacts with upstream bind-
ing factor-1 (UBF1) and regulates RNA polymerase activ-
ity to increase ribosomal RNA synthesis [173].
A role for IRS-1 in DNA repair has also been reported. In
normal cells, IRS-1 binds to Rad51, a key enzyme in
homologous recombination-directed DNA repair (HRR),
and regulates its recruitment into the nucleus in response
to agents that cause double strand breaks [174]. Phospho-
rylation of IRS-1 on tyrosine residues disrupts its interac-
tion with Rad-51 and allows Rad51 to translocate into the
nucleus to initiate DNA repair. In the absence of IGF-1 sig-
naling, the IRS-1/Rad51 interaction is maintained and
repair is impeded [174]. In medulloblastomas, IRS-1
translocates to the nucleus with ERβ or the JCV T-antigen,
where it interacts with Rad51 and prevents HRR, render-
ing these tumors more sensitive to genotoxic agents such
as cisplatin [175,176].
Conclusion
The IRS proteins have been implicated in contributing to
all stages of cancer, from initiating events to metastatic
progression. However, there is still much to be learned
about the mechanisms by which each of the IRS proteins
differentially contribute to tumor cell function and the
manner in which their expression and function are regu-
lated. Understanding how the tumor microenvironment
and other oncogenic signaling pathways impinge upon
the IRS proteins to influence their signaling functions is
essential for the future development of these adaptor pro-
teins as either predictive markers for drug responsiveness
or as therapeutic targets themselves. Given that IRS-1 and
IRS-2 mediate distinct cellular responses to IGF-
1stimulation, their relative expression levels and func-
tional status are likely to impact the response of tumors to
therapies that target the IGF-1 signaling axis. Assays that
can determine not only the expression of the IRS family
members but also their functional status will need to be
developed to identify patients that are likely to be respon-
sive to this targeted therapy and what outcomes should be
anticipated.
The contribution of the IRS proteins to drug resistance is
another important area for future investigation. The
expression and function of the IRS proteins are tightly reg-
ulated by negative feedback loops, many of which are dis-
rupted by drugs that target oncogenic signaling pathways.
For example, prolonged inhibition of EGFR or MAPK sig-
naling prevents the MAPK-mediated degradation of IRS-1,
which increases IGF-1R signaling and resistance to EGFR-
inhibition therapy [177,178]. Likewise, resistance to
rapamycin treatment can occur through the upregulation
of IRS-1-mediated PI3K signaling that occurs due to the
disruption of S6-kinase-mediated degradation of the IRS
proteins [138,143]. Taken together, these studies reveal
the importance of negative feedback regulation of the IRSCell Communication and Signaling 2009, 7:14 http://www.biosignaling.com/content/7/1/14
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proteins and underscore the importance of assessing IRS
expression and function when designing new therapies
that will disrupt these feedback mechanisms.
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